Patents by Inventor Stefan Lindstrom
Stefan Lindstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210137886Abstract: The present invention relates to certain compounds that function as inhibitors of bacterial metallo-beta-lactamases. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of a bacterial infection.Type: ApplicationFiled: May 25, 2018Publication date: May 13, 2021Inventors: Johan GISING, Stefan LINDSTROM, Dmitry ANTONOV, Peter BRANDT, Anna Karin BELFRAGE, Jürgen BREM, Christopher J. SCHOFIELD
-
Patent number: 10946164Abstract: A breathing apparatus provides high frequency oscillatory ventilation [HFO] to a patient by supplying breathing gas to the patient according to an oscillating pressure profile oscillating between a positive pressure and a negative pressure. The breathing apparatus has a patient circuit including an inspiratory line for conveying breathing gas to the patient, and an expiratory line for conveying gas away from the patient, and an inspiration valve for regulating a flow of pressurised breathing gas into the inspiration line, and a control computer that controls the inspiration valve. The control computer operates to cause the oscillating pressure profile by controlling the inspiration valve to oscillate between a top flow position in which the flow of breathing gas through the inspiration valve assumes a top flow value, and a minimum flow position in which the flow through the inspiration valve assumes a minimum flow value.Type: GrantFiled: September 21, 2012Date of Patent: March 16, 2021Assignee: MAQUET CRITICAL CARE ABInventors: Stefan Lindström, Carl Erik Troili, Magnus Hallbäck
-
Publication number: 20150238724Abstract: A breathing apparatus provides high frequency oscillatory ventilation [HFO] to a patient by supplying breathing gas to the patient according to an oscillating pressure profile oscillating between a positive pressure and a negative pressure. The breathing apparatus has a patient circuit including an inspiratory line for conveying breathing gas to the patient and an expiratory line for conveying gas away from the patient, and an inspiration valve for regulating a flow of pressurised breathing gas into the inspiration line, and a control computer that controls the inspiration valve. The control computer operates to cause the oscillating pressure profile by controlling the inspiration valve to oscillate between a top flow position in which the flow of breathing gas through the inspiration valve assumes a top flow value, and a minimum flow position in which the flow through the inspiration valve assumes a minimum flow value.Type: ApplicationFiled: September 21, 2012Publication date: August 27, 2015Applicant: MAQUET CRITICAL CARE ABInventors: Stefan Lindström, Carl Erik Troili, Magnus Hallbäck
-
Publication number: 20130269635Abstract: The present invention relates to the replacement of water and glycol mixtures by a synthetically made diesel as cooling medium, for instance engine coolant in vehicles. The synthetic diesel is environmental-friendly, usable in a wide temperature range, functions as corrosion protection in radiator systems, and transports heat better than water does.Type: ApplicationFiled: December 16, 2010Publication date: October 17, 2013Applicant: EC1 INVENT ABInventors: Mats Arrhenborg, Stefan Lindstrom
-
Patent number: 8008251Abstract: Inhibitors of HCV of formula (I). and the N-oxides, salts, and stereoisomers thereof, wherein the dashed line represents an optional double bond between atoms C7 and C8; R1 is hydrogen or C1-6alkyl; R2 is hydrogen or C1-6alkyl; and n is 3, 4, 5, or 6; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I) are provided. Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.Type: GrantFiled: July 28, 2006Date of Patent: August 30, 2011Assignees: Tibotec Pharmaceuticals Ltd., Medivir ABInventors: Kenneth Alan Simmen, Herman Augustinus De Kock, Pierre Jean-Marie Bernard Raboisson, Mats Stefan Lindström, Pia Cecilia Kahnberg, Dmitry Antonov, Karl Magnus Nilsson, Bengt Bertil Samuelsson, Åsa Annica Kristina Rosenquist
-
Patent number: 7915295Abstract: Compounds of the formula Z: where; A is CH or N; R1 is a substituent to a carbon atom in the ring containing A selected from —S(?O)pRa, where Ra is —C1-C4 alkyl, —ORx, —NRxRx, —NHNRxRx, —NHNHC(?O)ORx, —NRxOH; —C(?O)—Rb, where Rb is —CT-C4-alkyl, ORx, —NRxRx, —NHNRxRx, —NHC1-C3-alkyl-C(?O)Orx —NRxRc, where Rc is H, C1-C4 alkyl, —NRxRx; —C(=0)Rd, —CN, S(?O)pRx, where Rd is Rd is C1-C4-alkyl, —ORx, —NRxRx C1-C3-alkyl-O—C1-C3-alkylC(?O)ORx, —C1-C3-alkyl-COORx; —C1-C3alkyl-OH or C1-C4 alkyl ethers or esters thereof (O—C1-C3alkyl)q-O—Rx a 5 or 6 membered aromatic ring having 1-3 hetero atoms p is 1 or 2; Rx is independently selected from H, C1-C4 alkyl or acetyl; or a pair of Rx can together with the adjacent N atom form a ring; L is -0-, —S(?O)—, or —CH2—, where r is 0, 1 or 2; R3-R7 are substituents as defined in the specification; X is —(CR8R8?)n-D-(CR8R8?)m-; D is a bond, —NR9—, -0-, —S—, —S(=0)- or —S(=0)2-; and pharmaceutically acceptable salts and prodrugs thereof, have utility as HIV antivirals.Type: GrantFiled: December 30, 2004Date of Patent: March 29, 2011Assignee: Medivir ABInventors: Christian Sund, Nathalie Roue, Stefan Lindstrom, Dmitry Antonov, Christer Sahlberg, Katarina Jansson
-
Patent number: 7659245Abstract: Compounds of the formula I: and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(?O)pR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; p is independently 1 or 2; n is 3, 4, 5 or 6; denotes an optional double bond; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl-carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl; R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl; R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatmeType: GrantFiled: July 28, 2006Date of Patent: February 9, 2010Assignee: Tibotec Pharmaceuticals LtdInventors: Kenneth Alan Simmen, Herman Augustinus De Kock, Pierre Jean-Marie Bernard Raboisson, Lili Hu, Karin Charlotta Lindquist, Mats Stefan Lindström, Anna Karin Gertrud Linnea Belfrage, Horst Jürgen Wähling, Karl Magnus Nilsson, Bengt Bertil Samuelsson, Åsa Annica Kristina Rosenquist, Sven Crister Sahlberg, Hans Kristian Wallberg, Pia Cecilia Kahnberg, Björn Olof Classon
-
Publication number: 20090118312Abstract: Compounds of the formula I: and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(?O)pR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; p is independently 1 or 2; n is 3, 4, 5 or 6; — denotes an optional double bond; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl-carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl; R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl; R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatType: ApplicationFiled: July 28, 2006Publication date: May 7, 2009Inventors: Kenneth Alan Simmen, Herman Augustinus De Kock, Pierre Jean-Marie Bernard Raboisson, Lili Hu, Karin Charlotta Lindquist, Mats Stefan Lindstrom, Anna Karin Gertrud Linnea Belfrage, Horst Jurgen Wahling, Karl Magnus Nilsson, Bengt Bertil Samuelsson, Asa Annica Kristina Rosenquist, Sven Crister Sahlberg, Hans Kristian Wallberg, Pia Cecilia Kahnberg, Bjorn Olof Classon
-
Patent number: 7517992Abstract: A compound of the formula (Y): where; R1 is O, S; R2 is a nitrogen-containing heterocycle; R3 is H, C1-C3 alkyl; X is —(CR8R8?)n-D-(CR8R8?)m—; D is a bond, —NR9—, —O—, —S—, —S(?O)— or —S(?O)2—; n and m are independently 0, 1 or 2, R8 and R8? are independently H, C1-C3 alkyl, haloC1-C3alkyl, hydroxy, or R8 and R8? together with their adjacent C atom is —C(?O)—; R9 is independently H, C1-C3 alkyl; E is CH2—, —CHOH—, —C(?O)—, —NR9—, —O—, —S—, —S(?O)2—; n and m are independently 0, 1 or 2; p and q are independently 0, 1 or 2, where p+q?2; R10 is an optionally substituted carbocycle or heterocycle; R11 is independently H, C1-C3 alkyl, halo substituted C1-C3alkyl, hydroxy; have utility as HIV antivirals.Type: GrantFiled: September 5, 2003Date of Patent: April 14, 2009Assignee: Medivir ABInventors: Dmitry Antonov, Christian Sund, Stefan Lindström, Christer Sahlberg
-
Publication number: 20080200503Abstract: Inhibitors of HCV of formula (I). and the N-oxides, salts, and stereoisomers thereof, wherein the dashed line represents an optional double bond between atoms C7 and C8; R1 is hydrogen or C1-6alkyl; R2 is hydrogen or C1-6alkyl; and n is 3, 4, 5, or 6; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I) are provided. Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.Type: ApplicationFiled: July 27, 2006Publication date: August 21, 2008Inventors: Kenneth Alan Simmen, Herman Augustinus De Kock, Pierre Jean-Marie Bernard Raboisson, Mats Stefan Lindstrom, Pia Cecilia Kahnberg, Dmitry Antonov, Karl Magnus Nilsson, Bengt Bertil Samuelsson, Asa Annica Kristina Rosenquist
-
Patent number: 7405310Abstract: This invention relates to non-nucleoside reverse transcriptase inhibitors active against HIV-1 and having an improved resistance and pharmacokinetic profile. The invention further relates to novel intermediates in the synthesis of such compounds and the use of the compounds in antiviral methods and compositions.Type: GrantFiled: March 2, 2005Date of Patent: July 29, 2008Assignee: Medivir ABInventors: Stefan Lindstrom, Christer Sahlberg, Hans Wallberg, Genaidy Kalyanov, Lourdes Salvador Oden, Lotta Naeslund
-
Publication number: 20080070951Abstract: Compounds of the formula Z: where; A is CH or N; R1 is a substituent to a carbon atom in the ring containing A selected from —S(?O)pRa, where Ra is —C1-C4 alkyl, —ORx, —NRxRx, —NHNRxRx, —NHNHC(?O)ORx, —NRxOH; —C(?O)—Rb, where Rb is —CT-C4-alkyl, ORx, —NRxRx, —NHNRxRx, —NHC1-C3-alkyl-C(?O)Orx —NRxRc, where Rc is H, C1-C4 alkyl, —NRxRx; —C(=0)Rd, —CN, S(?O)pRx, where Rd is Rd is C1-C4-alkyl, —ORx, —NRxRx C1-C3-alkyl-O—C1-C3-alkylC(?O)ORx, —C1-C3-alkyl-COORx; —C1-C3alkyl-OH or C1-C4 alkyl ethers or esters thereof (O—C1-C3alkyl)q-O—Rx a 5 or 6 membered aromatic ring having 1-3 hetero atoms p is 1 or 2; Rx is independently selected from H, C1-C4 alkyl or acetyl; or a pair of Rx can together with the adjacent N atom form a ring; L is —O —, —S(?O)—, or —CH2—, where r is 0, 1 or 2; R3-R7 are substituents as defined in the specification; X is —(CR8R8?)n-D-(CR8R8?)m-; D is a bond, —NR9—, —O—, —S—, —S(=0)- or —S(=0)2-; and pharmaceutically acceptable salts and prodrugs thereof, have utility as HIV antivirals.Type: ApplicationFiled: December 30, 2004Publication date: March 20, 2008Applicant: Medivir ABInventors: Christian Sund, Nathalie Roue, Stefan Lindstrom, Dmitry Antonov, Christer Sahlberg, Katarina Jansson
-
Publication number: 20060167055Abstract: A compound of the formula (Y): where; R1 is O, S; R2 is a nitrogen-containing heterocycle; R3 is H, C1-C3 alkyl; X is —(C8R8)n-D-(C8C8?)m—; D is a bond, —NR9—, —O—, —S—, —S(?O)— or —S(?O)2; n and m are independently 0, 1 or 2, R8 and R8? are independently H, C1-C3 alkyl, haloC1-C3alkyl, hydroxy, or R8 and R8? together with their adjacent C atom is —C(?O)—; R9 is independently H, C1-C3 alkyl; E is CH2—, —CHOH—, —C(?O)—, —NR9—, —O—, —S—, —S(?O)2—; n and m are independently 0, 1 or 2; p and q are independently 0, 1 or 2, where p+q?2; R10 is an optionally substituted carbocycle or heterocycle; R11 is independently H, C1-C3 alkyl, halo substituted C1-C3alkyl, hydroxy; have utility as HIV antivirals.Type: ApplicationFiled: September 5, 2003Publication date: July 27, 2006Applicant: Medivir ABInventors: Dmitry Antonov, Christian Sund, Stefan Lindstrom, Christer Sahlberg
-
Publication number: 20050240035Abstract: This invention relates to non-nucleoside reverse transcriptase inhibitors active against HIV-1 and having an improved resistance and pharmacokinetic profile. The invention further relates to novel intermediates in the synthesis of such compounds and the use of the compounds in antiviral methods and compositions.Type: ApplicationFiled: March 2, 2005Publication date: October 27, 2005Applicant: Medivir ABInventors: Stefan Lindstrom, Christer Sahlberg, Hans Wallberg, Genaidy Kalyanov, Lourdes Oden, Lotta Naeslund
-
Patent number: 6894177Abstract: Compounds of the formula I: where; R1 is O, S; R2 is an optionally substituted nitrogen-containing heterocycle, wherein the nitrogen is located at the 2 position relative to the (thio)urea bond; R3 is H, C1-C3 alkyl, R4-R7 are independently selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, haloC1-C6 alkyl, C1-C6 alkanoyl, haloC1-C6 alkanoyl, C1-C6 alkoxy, haloC1-C6 alkoxy, C1-C6 alkyloxy-C1-C6 alkyl, haloC1-C6 alkyloxy-C1-C6 alkyl hydroxy-C1-C6 alkyl, amino-C1-C6 alkyl, carboxy-C1-C6 alkyl, cyano-C1-C6 alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto; X is —(CH2)n?—D—(CH2)m—; D is —O—, —S—; n and m are independently 0 or 1; and prodrugs and pharmaceutically acceptable salts thereof, have utility as inhibitors of HIV-1 reverse transcriptase, particularly drug escape mutants.Type: GrantFiled: February 28, 2003Date of Patent: May 17, 2005Assignee: Medivir ABInventors: Stefan Lindström, Christer Sahlberg, Hans Wallberg, Genaidy Kalyanov, Lourdes Salvador Odén, Lotta Naeslund
-
Patent number: 6716850Abstract: Compounds of the formula I: where; R1 is O, S; R2 is an optionally substituted nitrogen-containing heterocycle, wherein the nitrogen is located at the 2 position relative to the (thio)urea bond; R3 is H, C1-C3 alkyl, R4-R7 are independently selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, haloC1-C6 alkyl, C1-C6 alkanoyl, haloC1-C6 alkanoyl, C1-C6 alkoxy, haloC1-C6 alkoxy, C1-C6 alkyloxy-C1-C6 alkyl, haloC1-C6 alkyloxy-C1-C6 alkyl hydroxy-C1-C6 alkyl, amino-C1-C6 alkyl, carboxy-C1-C6 alkyl, cyano-C1-C6 alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto; X is —(CHR8)n-—D—(CHR8)m—; D is —NR9—, —O—, —S—, —S(═O)— or —S(═O)2—; R8 is independently H, C1-C3 alkyl, halo substitutedC1-C3alkyl; R9 is H, C1-C3 alkyl; n and m are independently 0, 1 or 2; and prodrugs and pharmaceutically acceptable salts thereof, have utility as inhibitors of HIV-1 reverse transcriptase, particularType: GrantFiled: March 5, 2002Date of Patent: April 6, 2004Assignee: Medivir ABInventors: Stefan Lindström, Christer Sahlberg, Hans Wallberg, Genaidy Kalyanov, Lourdes Salvador Odén, Lotta Naeslund
-
Publication number: 20030186924Abstract: A method for treatment of HBV and HIV infections comprising administering the compound or salt of formula Ig 1Type: ApplicationFiled: November 16, 2001Publication date: October 2, 2003Applicant: MEDIVIR ABInventors: Xiao-Xiong Zhou, Nils Gunnar Johansson, Horst Wahling, Christian Sund, Hans Wallberg, Lourdes Salvador, Stefan Lindstrom, Christer Sahlberg
-
Publication number: 20030187266Abstract: Compounds of the formula I: 1Type: ApplicationFiled: February 28, 2003Publication date: October 2, 2003Applicant: Medivir ABInventors: Stefan Lindstrom, Christer Sahlberg, Hans Wallberg, Genaidy Kalyanov, Lourdes Salvador Oden, Lotta Naeslund
-
Publication number: 20030069224Abstract: Compounds of the formula I: 1Type: ApplicationFiled: March 5, 2002Publication date: April 10, 2003Applicant: Medivir ABInventors: Stefan Lindstrom, Christer Sahlberg, Hans Wallberg, Genaidy Kalyanov, Lourdes Salvador Oden, Lotta Naeslund
-
Patent number: 6458772Abstract: Compounds of the formula I or corresponding monohydroxynucleoside derivatives wherein: R1 is hydroxy, amino or carboxy: optionally having esterified/amide bonded thereon; a C4-C22 saturated or unsaturated, optionally substituted fatty acid or alcohol, or an aliphatic L-amino acid; R2 is the residue of an aliphatic L-amino acid; L1 is a trifunctional linker group; L2 is absent or a difunctional linker group; and pharmaceutically acceptable salts thereof have favorable pharmacological properties and are antivirally active.Type: GrantFiled: February 12, 1999Date of Patent: October 1, 2002Assignee: Medivir ABInventors: Xiao-Xiong Zhou, Nils Gunnar Johansson, Horst Wahling, Christian Sund, Hans Wallberg, Lourdes Salvador, Stefan Lindstrom, Christer Sahlberg